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Wilson’s disease (WD) is a rare, progressive autosomal recessive disorder characterised by impaired 
transport and excessive accumulation of copper in the liver, brain, and other tissues. The disease is diagnosed 
based on clinical manifestations and screening tests results. Work ability assessment of patients with WD 
is based on the analysis of liver, kidney, neurological, and cognitive impairments, and takes into account 
patient’s level of education.
This article presents a case with a 48-year-old male patient, who was admitted for work ability assessment 
due to polymorphic symptoms. The patient had been working as a salesman for 28 years. A detailed 
interview and examination by occupational health and other medical specialists revealed that the patient 
had been suffering from Wilson’s disease from the age of 13, and had now developed hepatic manifestations 
(compensated liver cirrhosis with portal hypertension), neurological manifestations (dystonia, dysarthria, 
muscle weakness, vertigo), and psychiatric manifestations (depression, insomnia, cognitive impairment) 
of the disease, including problems partially caused by long-lasting treatment with copper chelating agents 
(neurological and haematological manifestations). There were no ocular manifestations of Wilson’s disease 
(Kayser-Fleischer rings or sunfl ower cataract).
The patient was assessed as having drastically diminished general work ability, dominantly due to 
neurological and psychiatric impairments caused by Wilson’s disease.
KEY WORDS: chelation therapy, cognitive impairment, copper, depression, disability evaluation, D-
penicillamine, dysarthria, dystonia, insomnia, Kayser-Fleischer rings, liver cirrhosis, muscle weakness, 
portal hypertension, psychiatric disorders, vertigo
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Wilson’s disease (WD) is a progressive autosomal 
recessive disorder characterised by impaired copper 
transport and excessive accumulation of copper in the 
liver, brain, and other tissues. It has been named after 
S. A. Kinnier Wilson, who fi rst described it in detail 
in Brain in 1912, addressing both pathological and 
clinical manifestations (1).
Wilson’s disease is caused by a mutation in the 
ATP7B gene, located in chromosome 13, which 
encodes a Copper-Binding P-type ATPase, expressed 
dominantly in the liver cells and vital for the 
transmembrane transport of copper (2-5). Impaired 
function of this enzyme leads to decreased excretion 
of copper from the liver cells into bile. Consequently, 
copper accumulates in the liver cells, disrupting their 
structure and function. In addition, it is released into 
the blood stream and transported to other target organs 
such as the brain, kidneys, and eyes, where it also 
accumulates and does damage.
It is a rare disease, with average prevalence of 30 
per million population (6, 7). Its diagnosis is based on 
clinical manifestations and screening test results. 
Clinical manifestations include liver disease (hepatitis, 
cirrhosis, liver failure), progressive neurological 
164
disorder (dystonia, tremor, dysphagia, dysarthria), and 
a psychiatric illness (depression, cognitive and 
emotional impairment) (7, 8). Screening tests include 
24-h urine copper excretion, serum and urine copper 
levels, ceruloplasmin serum level, and eye examination 
for Kayser-Fleischer ring with a slit lamp. The 
definitive diagnostic test is quantitative analysis of 
copper in a dry liver tissue sample obtained by 
percutaneous liver biopsy (9).
Work ability assessment of patients with WD is 
based on the analysis of liver, kidney, neurological, 
and cognitive impairment, and takes into account 
patient’s level of education (10).
CASE REPORT
A 48-year old male patient D. M. was admitted for 
work ability assessment to the Serbian Institute for 
Occupational Health. His main symptoms were 
weakness in arms and legs, tremor, general fatigue, 
insomnia, headache, anxiety, blurry vision, 
forgetfulness, and vertigo.
Patient’s history revealed that he had a severe 
hepatitis-like liver disease at the age of 10, that he was 
diagnosed Wilson’s disease at the age of 13, and that 
he had been treated with D-penicillamine from the age 
of 14. The fi rst administration of D-penicillamine 
worsened the symptoms and led to high fever and 
intense neurological problems, including a weakness 
of the left arm and leg, dysphagia, and dysarthria. 
Withdrawal of D-penicillamine relieved the symptoms, 
but some neurological issues remained. Since then, 
the patient had been monitored closely, as he continued 
treatment with D-penicillamine (500 mg three times 
a day) and pyridoxine oral preparations (20 mg three 
times a day). Over the last three years, his health got 
worse, especially the neurological problems, and he 
developed new psychiatric and vision problems 
(blurry vision, impaired vision of the left eye). He 
denied having any new manifestations of the liver 
disease, but he had been told at earlier examinations 
that he had enlarged liver and spleen. The patient 
reported no other co-morbidities of interest or 
allergies; he did not smoke and did not drink 
alcohol.
Family history revealed that his mother had died 
of liver tumour, but none of his close relatives suffered 
from other chronic illnesses.
Occupational history showed that the patient had 
fi nished primary school, but could not pursue further 
education, except basic vocational training for a 
salesperson, due to a “learning disability” to use his 
own words. He had been selling alcoholic and non-
alcoholic drinks for 28 years. The initial clinical 
examination performed by an occupational health 
specialist revealed that the patient was obese, had 
normal vital signs, distended abdomen painful on 
palpation, and signs of enlarged liver at the level of 
the right rib arch. Upper extremities showed signs of 
involuntary tremor, and lower legs were swollen and 
skin hyperpigmented bilaterally.
To confi rm previous WD diagnosis, we performed 
screening tests. Complete blood count was normal 
save for a mild platelet defi ciency (145 x 109 L-1; 
reference interval 158 x 109 L-1 to 424 x 109 L-1). Liver 
function test was also normal, save for higher direct 
bilirubin (5.9 μmol L-1;  reference threshold 
<3.4 μmol L-1) and total bilirubin (22.3 μmol L-1; 
reference interval 5.1 μmol L-1 to 20.5 μmol L-1). 
Serum ceruloplasmin levels were signifi cantly lower 
than normal (0.02 g L-1; reference interval 0.2 g L-1 to 
0.6 g L-1). Serum copper level was lower than normal 
(3.3 μmol L-1; reference interval 10 μmol L-1 to 
22 μmol L-1), and 24-h urine copper was 6.51 μmol 
(reference threshold <0.6 μmol).
Abdominal ultrasound confi rmed enlarged liver 
(cephalic-caudal diameter of the right lobe was 16 cm) 
in the state of compensated cirrhosis and enlarged 
spleen (15.5 cm x 6 cm) with signs of portal 
hypertension.
Detailed neurological examination showed 
spasmodic dystonia and muscle weakness of the left 
arm, weakness and slower refl exes of the left leg, 
positive Romberg test, and severe dysarthria. On MRI, 
T2-weighted images revealed hyperintensities in the 
region of tegmentum mesencephali and putamen 
bilaterally. Cortical and subcortical reduction changes 
were also seen, as well as microvascular ischemic 
lesions in the region of centrum semiovale.
A detailed psychological and psychiatric 
examination showed borderline intelligence (IQ=78), 
with indicators of secondary cognitive deficit. 
Cognitive functions were substantially diminished. 
There were signs of emotional lability with 
autoagressive behaviour. There were no data available 
that would indicate any cognitive or emotional issues 
during early childhood, that is, before the first 
manifestations of the illness came through or before 
the initial D-penicillamine treatment.
Eye examination with a slit lamp showed no 
presence of Kayser-Fleischer rings, but there were 
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signs of hypermetropia, presbyopia, and anysometropia. 
The difference between the left and the right eye was 
more than 3 dioptres.
Dermatological examination showed signs of stasis 
dermatitis due to compromised peripheral circulation 
in the lower extremities.
DISCUSSION
Initial clinical manifestations of Wilson’s disease 
can involve neurological (in 40 % to 60 % of the 
patients) or liver function impairments (in 40 % to 
50 % of the patients) (7). Earlier onset of the disease 
is more often seen in patients with liver disease (11.4 
years vs. 18.9 years in patients with neurological 
forms) (11). When diagnosed WD at the age of 13, 
our patient had acute hepatitis-like symptoms and 
signs. They seem to appear fi rst in over 25 % of WD 
patients (12). Current liver function in our patient is 
also very common and involves progressive hepatic 
cirrhosis with enlarged liver and spleen and signs of 
portal hypertension. This level of liver disease alone 
is a contraindication for any kind of work that involves 
lifting heavy loads and dealing with hepatotoxic 
chemical agents (10).
Neurological impairment in WD can be classified 
as: (a) an akinetic-rigid syndrome similar to Parkinson’s 
disease, (b) pseudosclerosis dominated by tremor, (c) 
ataxia, and (d) a dystonic syndrome (13). Our patient 
mostly had dystonic manifestations, with some 
elements of pseudosclerosis.
Characteristic MRI changes in WD patients include 
lesions in the putamen, globus pallidus, caudate, 
thalamus, midbrain, pons, and cerebellum as well as 
cortical atrophy and white matter changes. In general, 
these lesions show high T2 and low T1 signal intensity 
(15). Our patient’s MRI showed hyperintensities in 
the region of tegmentum mesencephali and putamen 
bilaterally. In addition, we observed cortical and 
subcortical reduction changes, which are in line with 
MRI changes characteristic for WD.
Neurological manifestations of Wilson’s disease 
usually include resting or postural tremor, dysarthria 
(85 to 97 % of those with neurologic WD have this 
sign) (15), dystonia (11% to 65 % of WD patients) 
(16), dysphagia, drooling, headaches, and insomnia 
(9). Our patient had dominantly suffered from 
spasmodic dystonia of the left arm and leg and from 
severe dysarthria, vertigo, headaches, and insomnia.
In terms of work ability, this level of neurological 
impairment in conjunction with specifi c MRI changes 
is contraindicated for any kind of work, due to tremor, 
muscle weakness, and speech problems, but most of 
all, due to progressive and irreversible nature of the 
disease itself (17).
Psychiatric manifestations like depression, 
personality changes, and cognitive impairment are 
present in 20% to 65 % of patients with WD, especially 
in those with dominant neurological form the disease 
(12). Psychiatric examination of our patient showed 
signs of emotional lability with autoagressive 
behaviour, borderline intelligence, and diminished 
cognitive functions. These characteristics alone 
indicate work disability for all jobs that include 
psychological or physical strain.
Kayser-Fleischer (KF) rings are very common in 
patients with neurological and psychiatric 
manifestations of Wilson’s disease, but our patient had 
never had them. Ross et al. (18) have also reported 
about the absence of Kayser-Fleischer rings in patients 
with WD (18).
One of the basic aims of medical treatment of WD 
is to eliminate excess copper from the body and to 
prevent its further accumulation. In 1956, John Walshe 
(19) introduced D-penicillamine as a successful 
copper chelating agent. D-penicillamine stimulates 
urinary excretion of copper and promotes the synthesis 
of metallothionein, which in turn prevents tissue 
accumulation of copper. D-penicillamine is still one 
of the most important medications in the treatment of 
WD, but its wide use has shown some downsides. 
Initial high doses of D-penicillamine can further 
impair the neurological function of WD patients, and 
this impairment has been reported to persist in as many 
as 50 % of patients after stopping D-penicillamine 
treatment (7, 20). These fi ndings are in compliance 
with our patient’s history, as he showed worsening of 
neurological symptoms after the drug was introduced 
at the age of 14 and their persistence after it was 
stopped.
What is peculiar in this case is that no other 
medication (except pyridoxine supplementation) was 
included in our patient’s treatment. Nowadays zinc 
acetate, trientine, and ammonium tetrachydromolibdate 
are drugs of choice if D-penicillamine shows adverse 
effects (9). Furthermore, receiving 1500 mg of D-
penicillamine every day for 35 years could be one of 
the reasons for his progressive neurological 
deterioration over the past three years.
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CONCLUSIONS
Work ability assessment in patients suffering from 
Wilson’s disease most of all depends on the level of 
organ impairment (10, 17). Our patient had initially 
presented with the hepatic form of WD, complicated 
with neurological and cognitive impairment due to 
adverse effects of high dose D-penicillamine treatment. 
These cognitive impairments may have led to learning 
disabilities that limited our patient’s educational and 
occupational potentials. Due to early diagnosis and 
close monitoring, his liver function had been preserved 
for long; after 35 years with the diagnosis and 28 years 
of hard work, liver impairment was only at the level 
of compensated liver cirrhosis and portal hypertension. 
His neurological and psychiatric manifestations, on 
the other hand, had progressed far more after long-
term use of high-dose D-penicillamine, and are now 
the main reason for his drastically diminished work 
ability.
Even though our patient did not have eye 
manifestations of WD like KF rings and sunfl ower 
cataract, non-specifi c vision problems (hypermetropia, 
presbyopia, and anysometropia), mild trombocytopenia, 
and compromised peripheral circulation in the lower 
extremities also contributed to his work disability.
Acknowledgement
This report has been approved by the Institute’s 
Ethics Committee. The patient has consented to the 
publication of this report in a scientific journal, 
including all relevant data. This study was partly 
supported by the Serbian Ministry of Science and 
Technological Development (grant no. 175036).
REFERENCES
1. Kinnier Wilson SA. Progressive lenticular degeneration: a 
familial nervous disease associated with cirrhosis of the liver. 
Brain 1912;34:295-507.
2. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. 
The Wilson disease gene is a putative copper transporting 
P-type ATPase similar to the Menkes gene. Nat Genet 
1993;5:327-37.
3. Petrukhin K, Fischer SG, Piratsu M, Tanzi RE, Chernov I, 
Devoto M, Brzustowicz LM, Cayanis E, Vitale E, Russo JJ, 
Matseoane D, Boukhgalter B, Wasco W, Figus AL, Loudianos 
J, Cao A, Sternlieb I, Evgrafov O, Parano E, Pavone L, 
Warburton D, Ott J, Penchaszadeh GK, Scheinberg IH, 
Gilliam TC. Mapping, cloning and genetic characterization 
of the region containing the Wilson disease gene. Nat Genet 
1993;5:338-43.
4. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and 
characterization of a human liver cDNA as a candidate gene 
for Wilson disease. Biochem Biophys Res Commun 
1993;197:271-7.
5. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, 
Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, 
Devoto M, Peppercorn J, Bush AI, Sternlieb I, Pirastu M, 
Gusella JF, Evgrafov O, Penchaszadeh GK, Honig B, 
Edelman IS, Soares MB, Scheinberg IH, Gilliam TC. The 
Wilson disease gene is a copper transporting ATPase with 
homology to the Menkes disease gene. Nat Genet 1993;5:344-
50.
6. Frydman M. Genetic aspects of Wilson’s disease. J 
Gastroenterol Hepatol 1990;5:483-90.
7. Brewer GJ. Wilson’s disease: A Clinician’s Guide to 
Recognition, Diagnosis, and Management. Norwell (MA): 
Kluwer Academic Publishers; 2001.
8. Brewer GJ, Askari FK. Wilson’s disease: clinical management 
and therapy. J Hepatol 2005;42(Suppl 1):S13-21.
9. Roberts EA, Schilsky ML. A practice guideline on Wilson 
disease. Hepatology 2003;37:1475-92.
10. Vidaković A. [Ocenjivanje radne sposobnosti obolelih od 
najčešćih bolesti jetre i žučne kesice, in Serbian]. In: 
Vidaković A, Pavlović MŽ, editors. Ocenjivanje radne 
sposobnosti. Lazarevac: Elvod print; 2003. p. 378-9.
11. Walshe JM. Wilson’s disease (HLD). In: Vinken PJ, Bruyn 
GW, editors. Handbook of clinical neurology. Vol. 27. 
Amsterdam: North Holland Publishing Company; 1976. p. 
379-414.
12. Pffeifer RF. Wilson’s disease. Semin Neurol 2007;27:123-
32.
13. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. 
Wilson’s disease. Lancet 2007;369:397-408.
14. Sinha S, Taly AB, Ravishankar S, Prashanth LK, Venugopal 
KS, Arunodaya GR, Vasudev MK, Swamy HS. Wilson’s 
disease: cranial MRI observations and clinical correlation. 
Neuroradiology 2006;48:613-21.
15. Machado A, Chien HF, Deguti MM, Cançado E, Azevedo 
RS, Scaff M, Barbosa ER. Neurological manifestations in 
Wilson’s disease: Report of 119 cases. Mov Disord 
2006;21:2192-6.
16. Svetel M, Kozić D, Stefanova E, Semnić R, Dragašević N, 
Kostić VS. Dystonia in Wilson’s disease. Mov Disord 
2001;16:719-23.
17. Vuletin-Lekić V. [Ocenjivanje radne sposobnosti obolelih od 
najčešćih neuroloških bolesti, in Serbian]. In: Vidaković A, 
Pavlović MŽ, editors. Ocenjivanje radne sposobnosti. 
Lazarevac: Elvod print; 2003. p. 427-8.
18. Ross ME, Jacobson IM, Dienstag DL, Martin JB. Late onset 
Wilson’s disease with neurological involvement in the 
absence of Kayser-Fleischer rings. Ann Neurol 1985;17:411-
3.
19. Walshe JM. Penicillamine, a new oral therapy for Wilson’s 
disease. Am J Med 1956;21:487-95.
20. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of 
neurologic syndrome in patients with Wilson’s disease with 
initial penicillamine therapy. Arch Neurol 1987;44:490-3.
Popević MB, et al. WORK ABILITY ASSESSMENT IN WILSON’S DISEASE
Arh Hig Rada Toksikol 2011;62:163-167
167
Sažetak
OCJENA RADNE SPOSOBNOSTI PACIJENTA S WILSONOVOM BOLESTI - PRIKAZ 
BOLESNIKA
Wilsonova je bolest rijetka, progresivna autosomno recesivna bolest karakterizirana poremećajem transporta 
bakra i posljedičnim prekomjernim nakupljanjem bakra u jetri, mozgu i drugim tkivima i organima. 
Dijagnoza bolesti postavlja se na osnovi kliničkih manifestacija bolesti i nalaza laboratorijskih ispitivanja. 
Ocjena radne sposobnosti pacijenata s Wilsonovom bolesti zasniva se na analizi postojanja oštećenja i 
stupnja oštećenja hepatičkih, neuroloških, bubrežnih i kognitivnih funkcija, kao i na analizi stupnja 
obrazovanja pacijenata.
Prikazan je slučaj D. M., 48-godišnjeg pacijenta, koji je primljen zbog polimorfnih tegoba na bolničko 
ispitivanje radi ocjene radne sposobnosti. Pacijent je radio kao prodavač posljednjih 28 godina. Nakon 
detaljne anamneze i pregleda koje su obavili specijalisti medicine rada i drugi specijalisti utvrđeno je da 
pacijent boluje od Wilsonove bolesti od 13. godine života i da u ovom trenutku ima izražene hepatične 
manifestacije (kompenzirana ciroza jetre s portalnom hipertenzijom), neurološke manifestacije (distonija, 
dizartrija, mišićna slabost, vrtoglavica) i psihijatrijske manifestacije (depresija, nesanica, kognitivno 
oštećenje) Wilsonove bolesti, kao i da su prisutne tegobe djelomično uzrokovane dugotrajnom upotrebom 
kelatne terapije (neurološki i hematološki poremećaji). Nisu uočene karakteristične očne promjene 
Wilsonove bolesti (Kayser-Fleischerov prsten, katarakta u obliku suncokreta).
Ocjenom radne sposobnosti utvrđeno je da pacijent ima drastično smanjenu radnu sposobnost pretežno 
zbog neuroloških i psihičkih poremećaja u sklopu Wilsonove bolesti.
KLJUČNE RIJEČI: bakar, ciroza jetre, depresija, distonija, dizartrija, D-penicilamin, Kayser-
Fleischerov prsten, kelatna terapija, kognitivno oštećenje, mišićna slabost, nesanica, portalna hipertenzija, 
vrtoglavica
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